Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU Phase II/III platform trial in dominantly inherited Alzheimer's disease
2024-515198-91-00Phase 3Authorised
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of etalanetug and lecanemab in Alzheimer's disease (AD) (7 arms), sponsored by Washington University School of Medicine. Planned start Jul 2024; status: authorised.
02
Drugs
etalanetuglecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-515198-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515198-91-00.